In this episode, Professor Debra Rowett is joined by Professor Andrew Wilson, Chair of the Pharmaceutical Benefits Advisory Committee and Dr Paul Kubler, Consultant Rheumatologist to discuss how b/tsDMARDs are funded in Australia, the policies and mechanisms that influence the cost to government and how the introduction of biosimilars affects the pricing of biologics on the PBS.